Press release

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,

articleCastle Biosciences, Inc.April 12, 20234/company/castle-biosciences-inc/news/castle-biosciences-to-present-at-the-22nd-annual-needham-virtual-healthcare
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

About this update from Castle Biosciences, Inc.

[{"type":"text","content":" FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 4:30 p.m. Eastern time.\n\n\nA live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.\n\n\nAbout Castle Biosciences\n\n\nCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.\n\n\nCastle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.\n\n\nDecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230412005085/en/\n\nInvestor Contact:\nCamilla Zuckero\[email protected]\n\n\nMedia Contact:\nAllison Marshall\[email protected]\n\n\nSource: Castle Biosciences, Inc.","length":4953,"tagName":"div"}]

More updates from Castle Biosciences, Inc.